References
- Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111:2962–2972.
- Spicka I. Advances in multiple myeloma therapy during two past decades. Comput Struct Biotechnol J. 2014;10:38–40.
- Chesi M, Bergsagel PL. Molecular pathogenesis of multiple myeloma: basic and clinical updates. Int J Hematol. 2013;97:313–323.
- Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015;125:3059–3068.
- Dimopoulos MA, Richardson PG, Moreau P, et al. Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol. 2015;12:42–54.
- Wang JH, Zhou WW, Cheng ST, et al. Downregulation of Sprouty homolog 2 by microRNA-21 inhibits proliferation, metastasis and invasion, however promotes the apoptosis of multiple myeloma cells. Mol Med Rep. 2015;12:1810–1816.
- Amodio N, Di Martino MT, Neri A, et al. Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma. Expert Opin Biol Ther. 2013;13:S125–S137.
- Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297.
- Ambros V. microRNAs: tiny regulators with great potential. Cell. 2001;107:823–826.
- Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell. 2012;148:1172–1187.
- Ouyang M, Li Y, Ye S, et al. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. PLoS One. 2014;9:e96228.
- Taverna S, Giallombardo M, Pucci M, et al. Curcumin inhibits in vitro and in vivo chronic myelogenous leukemia cells growth: a possible role for exosomal disposal of miR-21. Oncotarget. 2015;6:21918–21933.
- Ma ZL, Hou PP, Li YL, et al. MicroRNA-34a inhibits the proliferation and promotes the apoptosis of non-small cell lung cancer H1299 cell line by targeting TGFβR2. Tumour Biol. 2015;36:2481–2490.
- Liu G, Jiang C, Li D, et al. MiRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in gastric cancer. Tumour Biol. 2014;35:9801–9806.
- Khan AA, Penny LA, Yuzefpolskiy Y, et al. MicroRNA-17 ∼ 92 regulates effector and memory CD8 T-cell fates by modulating proliferation in response to infections. Blood. 2013;121:4473–4483.
- Hsu TI, Hsu CH, Lee KH, et al. MicroRNA-18a is elevated in prostate cancer and promotes tumorigenesis through suppressing STK4 in vitro and in vivo. Oncogenesis. 2014;3:e99.
- Lawrie CH. MicroRNAs and lymphomagenesis: a functional review. Br J Haematol. 2013;160:571–581.
- Han SB, Shin YJ, Hyon JY, et al. Cytotoxicity of voriconazole on cultured human corneal endothelial cells. Antimicrob Agents Chemother. 2011;55:4519–4523.
- Peng J, Thakur A, Zhang S, et al. Expressions of miR-181a and miR-20a in RPMI8226 cell line and their potential as biomarkers for multiple myeloma. Tumour Biol. 2015;36:8545–8552.
- Raimondi L, Amodio N, Di Martino MT, et al. Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity. Oncotarget. 2014;5:3039–3054.
- Liang Z, Li Y, Huang K, et al. Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. Pharm Res. 2011;28:3091–3100.
- Wang F, Li T, Zhang B, et al. MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun. 2013;434:688–694.
- Li XT, Wang HZ, Wu ZW, et al. miR-494-3p regulates cellular proliferation, invasion, migration, and apoptosis by PTEN/AKT signaling in human glioblastoma cells. Cell Mol Neurobiol. 2015;35:679–687.
- Fang Y, Xu C, Fu Y. MicroRNA-17-5p induces drug resistance and invasion of ovarian carcinoma cells by targeting PTEN signaling. J Biol Res (Thessalon). 2015;22:12.
- Yu T, Liu L, Li J, et al. MiRNA-10a is upregulated in NSCLC and may promote cancer by targeting PTEN. Oncotarget. 2015;6:30239–30250.
- Correia C, Schneider PA, Dai H, et al. BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood. 2015;125:658–667.
- Yaya K, Hind D, Meryem Q, et al. Single nucleotide polymorphisms of multidrug resistance gene 1 (MDR1) and risk of chronic myeloid leukemia. Tumour Biol. 2014;35:10969–10975.
- Tsubaki M, Komai M, Itoh T, et al. By inhibiting Src, verapamil and dasatinib overcome multidrug resistance via increased expression of Bim and decreased expressions of MDR1 and survivin in human multidrug-resistant myeloma cells. Leuk Res. 2014;38:121–130.